›› 2011, Vol. 31 ›› Issue (5): 598-.doi: 10.3969/j.issn.1674-8115.2011.05.016

• Original article (Clinical research) • Previous Articles     Next Articles

Relationship between single nucleotide polymorphisms of candidate genes and survival of patients with gastric cancer undergoing chemotherapy with capecitabine and paclitaxel

ZHENG Lei-zhen1, GU Jian-chun1, GONG Ji-fang3, LI Xiao-ping1, CHEN Si-yu1, ZHANG Li1, JIAO Xiao-dong2, WANG Jie-jun2   

  1. 1.Department of Oncology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China；2.Department of Oncology, Changzheng Hospital, The Second Military Medical University, Shanghai 200003, China；3.Department of Digestive Diseases, Beijing Cancer Hospital, Beijing 100142, China
  • Online:2011-05-28 Published:2011-05-27
  • Supported by:

    Shanghai Municipal Health Bureau Foundation, 2008135

PDF (PC)

1656

Abstract:

Objective To investigate the relationship between single nucleotide polymorphisms of tumor-associated candidate genes and survival of patients with gastric cancer undergoing chemotherapy with capecitabine and paclitaxel. Methods Ninety-three patients pathologically confirmed of gastric cancer were selected, and received chemotherapy with capecitabine and paclitaxel. Genotypes of protooncogene TP53 rs1042522 (G/C), metabolism-associated gene GSTP1 rs1695(A/G) and CYP11B2 rs1799998 (T/C), DNA repair-associated gene XRCC1 rs1799782 (C/T) and ERCC2 rs1799793 (G/A) were determined by TaqMan-MGB methods. The median survival time (MST) after chemotherapy was compared among patients with different genotypes, and influencing factors for prognosis were analysed. Results The median time of follow-up was 29.6 months, and MST was 34.93 months. TP53 rs1042522 (G/C) genotype was related to MST after chemotherapy, and patients with TP53 rs1042522 G/G genotype were borderline significantly higher than those with TP53 rs1042522 G/C+C/C genotype in MST (51.2 months vs 26.6 months, P=0.073). There was no significant correlation between the other gene polymorphisms and MST (P>0.05). Cox regression analysis revealed that gender, operation status and pathological staging were the main influencing factors for the prognosis of gastric cancer after chemotherapy. Conclusion Polymorphisms of TP53 (rs1042522 G/C) are marginally significantly associated with prognosis in patients with gastric cancer after chemotherapy with capecitabine and paclitaxel.

Key words: gastric cancer, DNA repair gene, single nucleotide polymorphism, capecitabine, paclitaxel